Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory.


Journal

BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391

Informations de publication

Date de publication:
07 2020
Historique:
received: 15 01 2020
revised: 14 05 2020
accepted: 02 06 2020
entrez: 28 7 2020
pubmed: 28 7 2020
medline: 22 6 2021
Statut: ppublish

Résumé

Diabetes is a highly prevalent disease worldwide and represents a challenge for patients and healthcare systems. This population-based study evaluated diabetes burden in Italy in 2018 by assessing all aspects of outpatient and hospital care. We investigated data of 11 300 750 residents in local health districts contributing to ARNO Diabetes Observatory (~20% of Italian inhabitants). All administrative healthcare claims were analyzed to gather information on access to medical resources. Subjects with diabetes, identified by antihyperglycemic drug prescriptions, disease-specific copayment exemption and hospital discharge codes, were compared with age, sex and residency-matched non-diabetic individuals. We identified 697 208 subjects with ascertained diabetes, yielding a prevalence of 6.2% (6.5% in men vs 5.9% in women, p<0.001). Age was 69±15 (mean±SD). As compared with non-diabetic subjects, patients with diabetes received more prescriptions of any drugs (+30%, p<0.001), laboratory tests, radiologic exams and outpatient specialist consultations (+20%, p<0.001) and were hospitalized more frequently (+86%, p<0.001), with a longer stay (+1.4 days, p<0.001). Although cardiovascular diseases accounted for many hospital discharge diagnoses, virtually all diseases contributed to the higher rate of hospital admissions in diabetic subjects (235 vs 99 per 1000 person-years, p<0.001). Healthcare costs were >2-fold higher in subjects with diabetes, mainly driven by hospitalizations and outpatient care related to chronic complications rather than to glucose-lowering drugs, diabetes-specific devices, or metabolic monitoring. The burden of diabetes in Italy is particularly heavy and, as a systemic disease, it includes all aspects of clinical medicine, with consequent high expenses in all areas of healthcare.

Identifiants

pubmed: 32713842
pii: 8/1/e001191
doi: 10.1136/bmjdrc-2020-001191
pmc: PMC7383948
pii:
doi:

Substances chimiques

Hypoglycemic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Nutr Metab Cardiovasc Dis. 2016 Dec;26(12):1104-1111
pubmed: 27817991
Diabet Med. 2012 Mar;29(3):385-92
pubmed: 21913971
Clinicoecon Outcomes Res. 2013 May 14;5:193-201
pubmed: 23696709
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):944-50
pubmed: 27289165
Diabetes Care. 2018 Mar;41(3):513-521
pubmed: 29330152
Nutr Metab Cardiovasc Dis. 2008 Dec;18(10):678-82
pubmed: 18395428
Diabetes Care. 2018 May;41(5):963-970
pubmed: 29475843
Diabetes Care. 1994 Jun;17(6):548-56
pubmed: 8082523
Curr Opin Investig Drugs. 2003 Sep;4(9):1088-94
pubmed: 14582453
Diabetes Care. 2000 Jun;23(6):759-64
pubmed: 10840992
BMJ Open Diabetes Res Care. 2016 Oct 10;4(1):e000197
pubmed: 27843551
Lancet Diabetes Endocrinol. 2016 Jun;4(6):479-80
pubmed: 27156052
Diabetes Care. 2012 Sep;35(9):e64
pubmed: 22923686
Nutr Metab Cardiovasc Dis. 2012 Aug;22(8):684-90
pubmed: 21907553
Diabetes Care. 1999 May;22(5):756-61
pubmed: 10332677
Nutr Metab Cardiovasc Dis. 2011 May;21(5):339-46
pubmed: 20153612
BMJ. 2019 Sep 11;366:l5003
pubmed: 31511236
J Diabetes Investig. 2013 Jul 8;4(4):355-60
pubmed: 24843679
Cardiovasc Diabetol. 2007 Feb 15;6:5
pubmed: 17302977
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
Nutr Metab Cardiovasc Dis. 2020 Jan 3;30(1):84-91
pubmed: 31757572
Nutr Metab Cardiovasc Dis. 2018 Mar;28(3):219-225
pubmed: 29337018
Eur J Health Econ. 2016 Mar;17(2):139-47
pubmed: 25427540
Epidemiol Prev. 2019 Jul-Aug;43(4 Suppl 2):17-36
pubmed: 31650804
Am J Gastroenterol. 2014 Jul;109(7):1020-5
pubmed: 24890439
Diabetologia. 2019 Jan;62(1):3-16
pubmed: 30171279
BMJ Open Diabetes Res Care. 2019 May 28;7(1):e000657
pubmed: 31245008
Nutr Metab Cardiovasc Dis. 2018 May;28(5):444-450
pubmed: 29519560
Diabetologia. 1995 Mar;38(3):318-25
pubmed: 7758879

Auteurs

Enzo Bonora (E)

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy enzo.bonora@univr.it.

Salvatore Cataudella (S)

CINECA, Casalecchio di Reno, Italy.

Giulio Marchesini (G)

Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.

Roberto Miccoli (R)

Diabetes and Metabolism, University of Pisa, Pisa, Italy.

Olga Vaccaro (O)

Department of Clinical and Experimental Medicine, University of Naples Federico II, Napoli, Italy.

Gian Paolo Fadini (GP)

Medicine, University of Padua, Padova, Italy.

Nello Martini (N)

Research and Health Foundation, Bologna, Italy.

Elisa Rossi (E)

CINECA, Casalecchio di Reno, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH